ライフサイエンスコーパス: grade

1 d preclinical platforms for testing therapies at each tumor grade.

2 grades with a previously established prognostic ordinality: grade 1 = no disease progression; grade 2 = development of va

3 ed prognostic ordinality: grade 1 = no disease progression; grade 2 = development of varices; grade 3 = bleeding alone; g

4 = no disease progression; grade 2 = development of varices; grade 3 = bleeding alone; grade 4 = nonbleeding single decomp

5 Thirteen percent of patients (n = 5) had treatment-related grade 3 or 4 adverse events.

6 Grade 3-4 atrial fibrillation occurred in one (1%) patient an

7 de 3-4 atrial fibrillation occurred in one (1%) patient and grade 3-4 bleeding occurred in three (3%) patients.

8 Methods: Forty-three patients with cerebral gliomas (9 low-grade, 34 high-grade; 9 primary tumors, 34 recurrent tumors)

9 grade 2 = development of varices; grade 3 = bleeding alone; grade 4 = nonbleeding single decompensation; grade 5 = more t

10 leeding alone; grade 4 = nonbleeding single decompensation; grade 5 = more than one decompensating event; and grade 6 = d

11 ensation; grade 5 = more than one decompensating event; and grade 6 = death.

12 -three patients with cerebral gliomas (9 low-grade, 34 high-grade; 9 primary tumors, 34 recurrent tumors) who had preoper

13 For grading, 34 (11.7%) were classified as Grade A, 193 (66.1%) as Grade B, and 65 (22.2%) as Grade C.

14 entional toxicity tables that include the incidence of high-grade adverse events, defined by the Common Terminology Crite

15 GRADE and Cochrane Effective Practice and Organisation of Car

16 This systematic review used the GRADE approach to compile evidence to inform the European Aca

17 ood cancers, few have been guided by biomarkers or clinical-grade assays developed to predict patient response and, ultim

18 ding, 34 (11.7%) were classified as Grade A, 193 (66.1%) as Grade B, and 65 (22.2%) as Grade C.

19 Older age (OR-1.07), grade B/C pancreatic fistula (OR-3.84), and epidural use (OR-

20 ified as Grade A, 193 (66.1%) as Grade B, and 65 (22.2%) as Grade C.

21 An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking c

22 window of over three years between the development of high-grade dysplasia and pancreatic cancer.

23 use of specific extraction methods may lead to standardised grade extracts, both from native raw materials and by-product

24 e Atlas from 110 patients from five institutions with lower-grade gliomas (World Health Organization grade II and III) we

25 aterials and Methods Data in patients with IDH-mutant lower-grade gliomas (World Health Organization grade II/III) and 1p

26 Using the GRADE (Grading of Recommendations, Assessment, Development, a

27 combined biopsy was associated with the fewest upgrades to grade group 3 or higher on histopathological analysis of surg

28 nce was observed in the 3-year incidence of late RT-related grade >= 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v

29 Median OS was 13 months (95% CI 10-18) for patients with grade >= 3 neutropenia and 10 months (95% CI 8-13) for patien

30 dverse events affected 71% of the patients, and 4 (7%) were grade >= 3.

31 Frisen grade >=3 (odds ratio [OR] 10.21, P < .0053) and cases with w

32 oint was safety and we observed 6 of 28 patients (21%) with grade >=3 immune-related adverse events, consisting of asympt

33 Demographic data, TBM severity grade, HIV co-infection status, and clinical endpoints by 3 m

34 stolic function was found in 23 (11%) patients, dysfunction grade I in 107 (51%), grade II in 31 (14.8%), and grade III i

35 tutions with lower-grade gliomas (World Health Organization grade II and III) were used in this study.

36 und in 23 (11%) patients, dysfunction grade I in 107 (51%), grade II in 31 (14.8%), and grade III in 49 (23.3%) patients,

37 h IDH-mutant lower-grade gliomas (World Health Organization grade II/III) and 1p/19q codeletion status determined with FI

38 sfunction grade I in 107 (51%), grade II in 31 (14.8%), and grade III in 49 (23.3%) patients, respectively.

39 trix Cluster 3), indicated poorer survival in patients with grade III tumors.

40 ually be targeted in a personalized approach of chronic low-grade inflammation.

41 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44).

42 licability of ATR-FTIR for the in situ determination of the grade of liver steatosis at the operation room as a fast, qua

43 (111)In-anti-gammaH2AX-TAT localizes preferentially in high-grade PanIN lesions but not in established PDAC.

44 upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy.

45 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gyn

46 In the present study, we report the production of a high-grade spinal cord glioma model in pigs using lentiviral gene

47 le of these adverse events or reflect the continuous, lower grade symptomatic toxicities that are particularly relevant t

48 ific tissues, to autoinflammatory diseases, which cause low-grade systemic inflammation and contribute to several common

49 tudents in computational and systems biology using research-grade technologies.

50 tology, lymphovascular invasion, hydronephrosis and/or high-grade upper tract disease(3-5).